PAKIANATHAN DEEPIKA 4

What Happened

• Director Deepika Pakianathan received an award of 15,508 restricted stock units (RSUs) from Karyopharm Therapeutics Inc. (KPTI) on 2026-05-21. The RSUs were granted at $0.00 (transaction code A — Award/Grant), so there was no cash paid and the immediate reported value is $0.
• The RSUs convert into common stock on a one-for-one basis and vest 100% on May 21, 2027. Delivery of the vested shares is deferred until the earlier of the director’s separation from service or a change-in-control event.

Key Details

• Transaction date: 2026-05-21; Filing date (Form 4): 2026-05-26 (appears filed late relative to the usual 2-business-day Form 4 deadline).
• Transaction type/code: Award/Grant (A) of RSUs.
• Shares/units granted: 15,508 RSUs; grant price reported as $0.00; immediate reported cash value $0.
• Shares owned after transaction: Not specified in the filing.
• Footnote: RSUs governed by Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan; convert 1-for-1 and have deferred delivery terms (see vesting/delivery conditions above).

Context

• This is a compensation award to a director, not an open-market purchase or sale — it does not directly reflect a purchase decision or immediate liquidity event. RSU grants are common for board compensation and align pay with future company performance or service.